Literature DB >> 31376008

Predictive factors for extraction of common bile duct stones during endoscopic retrograde cholangiopancreatography in Billroth II anatomy patients.

Jia-Su Li1, Duo-Wu Zou1, Zhen-Dong Jin1, Xin-Gang Shi1, Jie Chen1, Zhao-Shen Li2, Feng Liu3.   

Abstract

BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) for extraction of common bile duct (CBD) stones in Billroth II anatomy patients is still a technical challenge and factors affecting stone extraction have not yet been clarified. This study aimed to analyze our experience and evaluate potential factors affecting CBD stone extraction.
METHODS: A retrospective analysis of CBD stones patients with a history of Billroth II gastrectomy, who underwent therapeutic ERCP for stone extraction at our center from August 1999 to December 2017, was conducted. The outcomes of ERCP and potential factors affecting stone extraction were examined.
RESULTS: A total of 227 patients were enrolled, and 176 patients (77.5%) achieved technical success. The success rate of duodenal ampullary access and selective biliary cannulation was 84.1% (191/227) and 92.1% (176/191), respectively. The mean CBD diameter was 15 mm (range 6-35 mm), and the largest stone size was 13 mm (range 4-36 mm). CBD stones were ultimately removed in 137 patients (77.8%), and 105 patients (59.7%) for the first session. Mechanical lithotripsy was used in 17 patients (9.7%). The overall ERCP-related complication rate was 6.3% (11/176), including bleeding in 3 patients (1.7%) and mild pancreatitis in 6 patients (3.4%). The multivariate analysis indicated that CBD stone number ≥ 2 (OR 2.171; 95% CI 1.095-4.306; p = 0.027), and the largest CBD stone size ≥ 12 mm (OR 3.646; 95% CI 1.833-7.251; p < 0.001) were patient-related risk factors for failed stone removal; while the use of endoscopic papillary (large) balloon dilation (EPBD/EPLBD) (OR 0.291; 95% CI 0.147-0.576; p < 0.001) was a procedure-related protective factor for successful stone extraction.
CONCLUSIONS: ERCP is safe and effective for extraction of CBD stones in Billroth II anatomy patients. The number and the largest size of CBD stones, and the use of EPBD/EPLBD are predictive factors for CBD stone extraction.

Entities:  

Keywords:  Billroth II anatomy; Common bile duct stones; Endoscopic retrograde cholangiopancreatography; Predictive factors

Mesh:

Year:  2019        PMID: 31376008     DOI: 10.1007/s00464-019-07039-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  25 in total

1.  Outcomes of ERCP in Billroth II gastrectomy patients.

Authors:  Tae Young Park; Jong Sik Kang; Tae Jun Song; Sang Soo Lee; Hyuk Lee; Jung Sik Choi; Hong Jun Kim; Ji Woong Jang
Journal:  Gastrointest Endosc       Date:  2015-11-04       Impact factor: 9.427

2.  A lexicon for endoscopic adverse events: report of an ASGE workshop.

Authors:  Peter B Cotton; Glenn M Eisen; Lars Aabakken; Todd H Baron; Matt M Hutter; Brian C Jacobson; Klaus Mergener; Albert Nemcek; Bret T Petersen; John L Petrini; Irving M Pike; Linda Rabeneck; Joseph Romagnuolo; John J Vargo
Journal:  Gastrointest Endosc       Date:  2010-03       Impact factor: 9.427

Review 3.  A review of treatment options for bile duct stones.

Authors:  Takeshi Ogura; Kazuhide Higuchi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-08-08       Impact factor: 3.869

Review 4.  Current endoscopic strategies for managing large bile duct stones.

Authors:  Bhavesh Doshi; Ichiro Yasuda; Shomei Ryozawa; Guan Huei Lee
Journal:  Dig Endosc       Date:  2018-04       Impact factor: 7.559

5.  Endoscopic papillary large balloon dilation in Billroth II gastrectomy patients with bile duct stones.

Authors:  Cheol Woong Choi; Jung Sik Choi; Dae Hwan Kang; Bong Gap Kim; Hyung Wook Kim; Su Bum Park; Ki Tae Yoon; Mong Cho
Journal:  J Gastroenterol Hepatol       Date:  2012-02       Impact factor: 4.029

6.  ERCP in patients with prior Billroth II gastrectomy: report of 30 years' experience.

Authors:  Vincenzo Bove; Andrea Tringali; Pietro Familiari; Giovanni Gigante; Ivo Boškoski; Vincenzo Perri; Massimiliano Mutignani; Guido Costamagna
Journal:  Endoscopy       Date:  2015-03-02       Impact factor: 10.093

7.  What predicts failed cannulation and therapy at ERCP? Results of a large-scale multicenter analysis.

Authors:  E J Williams; R Ogollah; P Thomas; R F Logan; D Martin; M L Wilkinson; M Lombard
Journal:  Endoscopy       Date:  2012-06-13       Impact factor: 10.093

8.  Endoscopic papillary large balloon dilatation alone is safe and effective for the treatment of difficult choledocholithiasis in cases of Billroth II gastrectomy: a single center experience.

Authors:  Hui Won Jang; Kyong Joo Lee; Moon Jae Jung; Joo Won Jung; Jeong Youp Park; Seung Woo Park; Si Young Song; Jae Bock Chung; Seungmin Bang
Journal:  Dig Dis Sci       Date:  2013-02-08       Impact factor: 3.199

9.  FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma.

Authors:  Li Li; Wenqi Zhang; Shanshan Zhao; Mao Sun
Journal:  Saudi J Gastroenterol       Date:  2019 Nov-Dec       Impact factor: 2.485

10.  Endoscopic papillary large balloon dilation for the retrieval of bile duct stones after prior Billroth II gastrectomy.

Authors:  Kook Hyun Kim; Tae-Nyeun Kim
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

View more
  2 in total

Review 1.  Endoscopic management of difficult common bile duct stones: Where are we now? A comprehensive review.

Authors:  Alberto Tringali; Deborah Costa; Alessandro Fugazza; Matteo Colombo; Kareem Khalaf; Alessandro Repici; Andrea Anderloni
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

2.  Outcomes of laparoscopic common bile duct exploration (LCBDE) after failed endoscopic retrograde cholangiopancreatography versus primary LCBDE for managing cholecystocholedocholithiasis.

Authors:  Hanbaro Kim; Suk Pyo Shin; Ji Woong Hwang; Jung Woo Lee
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.